Daewoong Pharma Enters Biosimilar Market with Chime Biologics Partnership for Dupixent Biosimilar
核心洞察
Daewoong Pharmaceutical (搜索) and Chime Biologics (搜索) announced a strategic partnership on June 2, 2026, to develop and manufacture a dupilumab biosimilar referencing Dupixent.
Chime Biologics (搜索) will contribute its AI-enabled development platform and China-based bioprocess supply chain ecosystem to support Daewoong's first global biosimilar product.
Dupixent, co-developed by Sanofi and Regeneron, generated approximately $17.8 billion in global sales in 2025, making it a highly attractive target for biosimilar development.
South Korea's Daewoong Pharmaceutical (搜索) has taken a decisive step into the global biosimilar arena through a strategic partnership with China-based Chime Biologics (搜索), a biologics contract development and manufacturing organization (CDMO). Announced on June 2, 2026, the agreement centers on the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent, the blockbuster biologic co-developed by Sanofi and Regeneron Pharmaceuticals.
The collaboration represents Daewoong Pharmaceutical (搜索)'s full-fledged entry into the biosimilar sector, positioning the program as a key long-term growth engine for the South Korean company, whose pipeline spans preclinical to NDA-stage therapeutics across autoimmune diseases, metabolic disorders, fibrosis, and oncology.
Leveraging AI and Supply Chain Infrastructure
Under the terms of the partnership, Chime Biologics (搜索) will deploy its extensive end-to-end biosimilar development and commercialization capabilities. Central to the collaboration is the Chime AI Platform, an advanced AI-enabled development platform, alongside the Chime Innovation Alliance — a rapidly evolving bioprocess supply chain ecosystem in China. Chime Biologics, headquartered in China with major development hubs in Basel, Shanghai, and Wuhan, brings global CDMO expertise to support Daewoong's biosimilar ambitions.
Targeting a Blockbuster Biologic
Dupilumab, the reference product, is a monoclonal antibody therapy that treats immunological diseases by blocking interleukin-4 (搜索) (IL-4) and interleukin-13 (搜索) (IL-13) receptor signaling, thereby inhibiting type 2 inflammation. Dupixent is currently approved for the treatment of asthma (搜索), atopic dermatitis (搜索) (eczema), chronic obstructive pulmonary disease (搜索) (COPD), and several other inflammatory conditions.
According to industry estimates, Dupixent achieved approximately $17.8 billion in global sales in 2025, reinforcing its status as one of the world's best-selling biologics and a highly attractive target for biosimilar development. The program targets a rapidly expanding global immunology market driven by increasing demand for therapies addressing atopic dermatitis (搜索) and other Type 2 inflammatory diseases.
A Competitive Biosimilar Landscape
The Daewoong-Chime announcement follows a series of similar dupilumab biosimilar developments. In May 2025, Alvotech and Advanz disclosed their own dupilumab biosimilar program, and Formycon AG followed with an announcement in November 2025. The growing number of entrants underscores the commercial appeal of the dupilumab market as patent protections for the reference product draw closer to expiration across key markets.